Upregulation of <scp>RIG</scp>‐I is Critical for Responsiveness to <scp>IFN</scp>‐α Plus Anti‐<scp>PD</scp>‐1 in Colorectal Cancer
RIG-I is a promising biomarker for CRC immunotherapy, which provides a novel concept for combinatorial immunotherapy.
Authors
- Shilin Fang
- Jiayan Nie
- Yumei Ning (ORCID: https://orcid.org/0009-0006-2292-7642)
- Yifan Jia (ORCID: https://orcid.org/0000-0002-3601-9817)
- Qiu Zhao (ORCID: https://orcid.org/0000-0002-3230-6077)
- Fei Xu (ORCID: https://orcid.org/0000-0001-8543-6636)
- Yuntian Hong (ORCID: https://orcid.org/0000-0002-3546-1670)
- Haihang Nie
- Fan Wang (ORCID: https://orcid.org/0000-0002-3278-4319)
- Rui Zhou (ORCID: https://orcid.org/0000-0002-4880-0563)
- Yali Yu (ORCID: https://orcid.org/0000-0001-9680-5783)
- Jingkai Zhou
Institutions
- Wuhan University (CN)
- Hubei Provincial Center for Disease Control and Prevention (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/cam4.70802
- Citations
- 1
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- National Natural Science Foundation of China